MedTrace Logo

Intrathecal Dexmedetomidine vs Epinephrine

NCT06418308 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-01-07

No results posted yet for this study

Summary

Several studies have shown that adding dexmedetomidine or epinephrine to single-dose spinal analgesia preparations improves the length and/or speed of onset of the sensory block and post-operative pain management without increased negative side effects. To date, however, no study has compared adjunctive intrathecal dexmedetomidine to adjunctive intrathecal epinephrine in single-dose spinal analgesia. The purpose of this study is to determine if adjunctive intrathecal dexmedetomidine is non-inferior to adjunctive intrathecal epinephrine in providing better single-dose spinal analgesia during cesarean section.

Conditions

  • Cesarean Section
  • Anesthesia, Spinal

Interventions

DRUG

Dexmedetomidine

5 mcg of dexmedetomidine

DRUG

Epinephrine

200 mcg of epinephrine

DRUG

Standardized Spinal Mixture

Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.

Sponsors & Collaborators

Principal Investigators

  • Daniel Katz, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-17
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06418308 on ClinicalTrials.gov